Fulcrum Therapeutics (NASDAQ: FULC) — Perfil da empresa, notícias e dados financeiros
Fulcrum Therapeutics develops medicines for genetically defined rare diseases, focusing on advanced scientific research.
Fulcrum Therapeutics
Fulcrum Therapeutics (NASDAQ:FULC) focuses on developing transformative medicines to improve the lives of patients with genetically defined rare diseases. Dedicated to tackling conditions that have limited treatment options, the company leverages advanced scientific research to identify and address the root causes of these diseases. Their pipeline includes projects targeting sickle cell disease and facioscapulohumeral muscular dystrophy, among others. With a steadfast commitment, Fulcrum aims to deliver groundbreaking therapies that can offer renewed hope and tangible benefits to those they serve.
Resumo
Operações
Produtos e/ou serviços de Fulcrum Therapeutics
- Losmapimod, aimed at treating Facioscapulohumeral Muscular Dystrophy (FSHD), a progressive and debilitating muscle disorder, by reducing inflammation and muscle degeneration.
- ReDUX4, a Phase 2b trial drug to slow or halt the progression of FSHD by targeting the root genetic cause of the disease.
- FulcrumSeek, a proprietary product engine designed to identify drug targets by integrating genetic and phenotypic insights to accelerate therapeutics.'
- Fulcrum's partnership on discovering therapies for sickle cell disease using small molecule approaches to modulate gene expression.
- Development of therapies for beta-thalassemia, utilizing gene regulation mechanisms to increase hemoglobin production.
- Collaboration on advanced therapy projects leveraging CRISPR technology for precise gene editing in genetic disorders.
equipe executiva do Fulcrum Therapeutics
- Alexander C. SapirCEO, President & Director
- Alan A. MussoCFO, Treasurer & Principal Accounting Officer
- Curtis G. OltmansChief Legal Officer, Head of External Affairs & Corporate Secretary
- Bradley E. BernsteinFounder
- Michael R. GreenFounder
- Rudolf JaenischFounder
- Tsun-Huei LeeFounder
- Danny ReinbergFounder
- Iain FraserSenior Vice President of Early Development
- Bobby RiehleHead of Program Strategy & Vice President
Últimas notícias sobre a Fulcrum Therapeutics
Principais indicadores financeiros
Resultados divulgados pela Fulcrum Therapeutics, em USD.
- Cap. de mercado
- 286,4 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -1.2
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -84,8 mi | -74,9 mi | |
| 80 mi | -21,9 mi | -9,7 mi | |
| 2,8 mi | -110,7 mi | -97,3 mi | |
| 6,3 mi | -112,6 mi | -109,9 mi |